117 related articles for article (PubMed ID: 8808071)
1. When we "act" on ACT levels: activated clotting time measurements to guide heparin administration during and after interventional procedures.
Klein LW; Agarwal JB
Cathet Cardiovasc Diagn; 1996 Feb; 37(2):154-7. PubMed ID: 8808071
[TBL] [Abstract][Full Text] [Related]
2. Percutaneous transluminal coronary angioplasty: comparison of arterial vs. venous activated clotting time.
Pesola GR; Johnson A; Pesola DA
Cathet Cardiovasc Diagn; 1996 Feb; 37(2):140-4. PubMed ID: 8808068
[TBL] [Abstract][Full Text] [Related]
3. [The use of activated clotting time (ACT) to optimize heparinization during coronary angioplasty. The nursing personnel of the Hemodynamics Laboratory].
Dellavalle A; Steffenino G; Ribichini F; Russo P; Conte L; Conte E; Uslenghi E
G Ital Cardiol; 1995 Apr; 25(4):445-51. PubMed ID: 7642051
[TBL] [Abstract][Full Text] [Related]
4. Activated clotting time (ACT)-guided intravenous dalteparin dosing during percutaneous coronary intervention.
Marmur JD; Poludasu S; Feit A; Battala VR; Cavusoglu E
J Invasive Cardiol; 2008 Jul; 20(7):323-7. PubMed ID: 18599887
[TBL] [Abstract][Full Text] [Related]
5. [-Value of activated blood coagulation time in monitoring anticoagulation during coronary angioplasty-].
Kunert M; Sorgenicht R; Scheuble L; Ketteler T; Lürken E; Meyer I; Müller A; Emmerich K; Gülker H
Z Kardiol; 1996 Feb; 85(2):118-24. PubMed ID: 8650981
[TBL] [Abstract][Full Text] [Related]
6. Rational approach to use of heparin during cardiac catheterization in children.
Grady RM; Eisenberg PR; Bridges ND
J Am Coll Cardiol; 1995 Mar; 25(3):725-9. PubMed ID: 7860920
[TBL] [Abstract][Full Text] [Related]
7. Venous activated clotting time after intra-arterial heparin: effect of site of administration and timing of sampling.
Kerensky RA; Azar GJ; Bertolet B; Hill JA; Kutcher MA
Cathet Cardiovasc Diagn; 1996 Feb; 37(2):151-3. PubMed ID: 8808070
[TBL] [Abstract][Full Text] [Related]
8. Research review: use of activated clotting time to monitor heparin therapy in coronary patients.
Noureddine SN
Am J Crit Care; 1995 Jul; 4(4):272-7; quiz 278-9. PubMed ID: 7663590
[TBL] [Abstract][Full Text] [Related]
9. In vivo and in vitro evaluation of the heparin management test versus the activated coagulation time for monitoring anticoagulation level in aprotinin-treated patients during cardiac surgery.
Kim YS; Murkin JM; Adams SJ
Heart Surg Forum; 2004; 7(6):E599-604. PubMed ID: 15769695
[TBL] [Abstract][Full Text] [Related]
10. How much heparin do we really need to go on pump? A rethink of current practices.
Shuhaibar MN; Hargrove M; Millat MH; O'Donnell A; Aherne T
Eur J Cardiothorac Surg; 2004 Nov; 26(5):947-50. PubMed ID: 15519187
[TBL] [Abstract][Full Text] [Related]
11. A comparison of activated coagulation time-based techniques for anticoagulation during cardiac surgery with cardiopulmonary bypass.
Slight RD; Buell R; Nzewi OC; McClelland DB; Mankad PS
J Cardiothorac Vasc Anesth; 2008 Feb; 22(1):47-52. PubMed ID: 18249330
[TBL] [Abstract][Full Text] [Related]
12. Anticoagulation and pediatric extracorporeal membrane oxygenation: impact of activated clotting time and heparin dose on survival.
Baird CW; Zurakowski D; Robinson B; Gandhi S; Burdis-Koch L; Tamblyn J; Munoz R; Fortich K; Pigula FA
Ann Thorac Surg; 2007 Mar; 83(3):912-9; discussion 919-20. PubMed ID: 17307433
[TBL] [Abstract][Full Text] [Related]
13. Use of the activated clotting time in anticoagulation monitoring of intravascular procedures.
Bowers J; Ferguson JJ
Tex Heart Inst J; 1993; 20(4):258-63. PubMed ID: 8298321
[TBL] [Abstract][Full Text] [Related]
14. Are activated clotting times helpful in the management of anticoagulation with subcutaneous low-molecular-weight heparin?
Henry TD; Satran D; Knox LL; Iacarella CL; Laxson DD; Antman EM
Am Heart J; 2001 Oct; 142(4):590-3. PubMed ID: 11579347
[TBL] [Abstract][Full Text] [Related]
15. Whole blood coagulation analyzers.
Health Devices; 1997 Aug; 26(8):296-332. PubMed ID: 9283920
[TBL] [Abstract][Full Text] [Related]
16. The activated clotting time (ACT) can be used to monitor enoxaparin and dalteparin after intravenous administration.
Cavusoglu E; Lakhani M; Marmur JD
J Invasive Cardiol; 2005 Aug; 17(8):416-21. PubMed ID: 16079447
[TBL] [Abstract][Full Text] [Related]
17. Monitoring activated clotting time for combined heparin and aprotinin application: in vivo evaluation of a new aprotinin-insensitive test using Sonoclot.
Ganter MT; Monn A; Tavakoli R; Genoni M; Klaghofer R; Furrer L; Honegger H; Hofer CK
Eur J Cardiothorac Surg; 2006 Aug; 30(2):278-84. PubMed ID: 16828293
[TBL] [Abstract][Full Text] [Related]
18. A novel point-of-care assay for the monitoring of low-molecular weight heparins in the cardiac catheterization laboratory.
Marmur JD; Lakhani M; El Rouby S; Cavusoglu E
J Invasive Cardiol; 2008 Sep; 20(9):449-54. PubMed ID: 18762674
[TBL] [Abstract][Full Text] [Related]
19. Comparison of activated clotting times to heparin management test for adequacy of heparin anticoagulation in percutaneous transluminal coronary angioplasty.
Helft G; Choktron S; Beygui F; Le Feuvre C; Elalamy I; Metzger JP; Vacheron A; Samama MM
Cathet Cardiovasc Diagn; 1998 Nov; 45(3):329-31. PubMed ID: 9829899
[TBL] [Abstract][Full Text] [Related]
20. The use of activated clotting times to monitor heparin therapy during and after interventional procedures.
Bowers J; Ferguson JJ
Clin Cardiol; 1994 Jul; 17(7):357-61. PubMed ID: 8088021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]